Mr. Michael Finamore is the CEO of Gemini Pharmaceuticals, Inc., a contract manufacturer of both dietary supplements and OTC pharmaceuticals. With his strategic stewardship, Gemini enjoys robust growth, standing as one of only a handful of manufacturers with global accreditation including dual US FDA registration (drugs and dietary supplements), NSF International GMP certification, TGA (Australia) registration and certification, Health Canada registration, among others. Emphasizing solid dose R&D and product development, Gemini produces more than 12-billion unit doses of dietary supplements and OTC drugs annually for more than eighty countries worldwide.
Additionally, Mr. Finamore has been selected as the inaugural Chairman of the Governance Board of the GRMA (Global Retailer & Manufacturer Alliance). The GRMA is a member-based organization chartered to strengthen quality and safety throughout the supply chain, comprised of more than 30 major retailers, quality certification bodies and manufacturers. GRMA has since published an ANSI-accredited public standard and audit scheme (NSF/ANSI 455), which is recognized as the premier GMP audit for inspecting providers of OTC Drugs, Dietary Supplements and Cosmetics.
Mr. Finamore also has been named to the Board of Directors of the Council of Responsible Nutrition (CRN), recognized as the leading trade association for the dietary supplement and functional food industry.
Previously, Mr. Finamore was an Assistant District Attorney for the State of New York (Suffolk County), handling both high-profile cases and numerous jury trials, and he continues to be admitted to the NYS Supreme Court and the US Supreme Court. Moreover, Mr. Finamore is a standing member of the American Bar Association as well as the NYS Bar Association, Food and Drug Law Committee.
Mr. Finamore also is the executive editor of key industry white papers and frequent expert contributor to important industry publications, such as Natural Products INSIDER.